Arcus Biosciences
RCUS
148 hedge funds and large institutions have $1.25B invested in Arcus Biosciences in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 53 reducing their positions, and 24 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
8% more capital invested
Capital invested by funds: $1.16B → $1.25B (+$97M)
4% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 24
0% more funds holding
Funds holding: 148 → 148 (0)
4% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 53
5.57% less ownership
Funds ownership: 68.69% → 63.12% (-5.6%)
76% less call options, than puts
Call options by funds: $3.19M | Put options by funds: $13.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$43.1M |
| 2 |
HM
HealthCor Management
New York
|
+$18.7M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$13.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$11.9M |
| 5 |
Renaissance Technologies
New York
|
+$8.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$30.5M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$20M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
-$11.4M |
| 4 |
Alkeon Capital Management
New York
|
-$10.6M |
| 5 |
CCM
Consonance Capital Management
New York
|
-$10.1M |
RCUS Hedge Fund Activity: Q1 2021 in Review
148 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2021, worth a combined $1.25B — up 8.4% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new RCUS positions and 24 closed out — a net gain of 1 holder — while 51 added to existing stakes and 53 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $43.1M. The largest seller was BVF Inc, cutting an estimated $30.5M.
- 148 institutional investors held Arcus Biosciences (RCUS) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $1.25B of Arcus Biosciences stock for Q1 2021, up 8.4% quarter-over-quarter.
- 25 funds opened new Arcus Biosciences positions in Q1 2021 and 24 closed out, a net change of +1 holder.
- The largest Arcus Biosciences buyer in Q1 2021 was Woodline Partners, an estimated $43.1M added.
- The largest Arcus Biosciences seller in Q1 2021 was BVF Inc, an estimated $30.5M sold.
Based on aggregated 13F filings for Q1 2021.